Zymeworks names Suzanne Monahan as SVP Commercial for YUPELRI

Zymeworks Inc. (Nasdaq: ZYME) has appointed Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma, effective immediately, according to a company statement.

Monahan will report directly to Kenneth Galbraith, Chair and Chief Executive Officer, and will lead commercial strategy and execution for YUPELRI (revefenacin), a once-daily, nebulized long-acting muscarinic antagonist approved in the U.S. for the maintenance treatment of chronic obstructive pulmonary disease. The appointment follows Zymeworks' acquisition of Theravance Biopharma.

Monahan brings more than 20 years of commercial experience in the pharmaceutical and medical device industries. She most recently served as Senior Vice President at Pacira BioSciences, where she oversaw multiple sales forces and a strategic partnerships group. Before that, she spent more than five years at Shionogi Inc., most recently as Vice President, Sales, where she led the launch of a hospital-based IV anti-infective. She also served as Vice President, Business Unit at Circassia Pharmaceuticals, leading a respiratory diagnostic device business. Earlier in her career, she held roles at Sanofi-Aventis and Salix Pharmaceuticals, including National Sales Director, Institutional, Federal and Specialty Accounts. She holds a B.A. in Psychology with a minor in Marketing from Quinnipiac University.

"Her track record of driving sustained growth and her deep experience in market access and strategic collaborations make her ideally suited to lead our commercial efforts for YUPELRI," Galbraith said.

You May Also Be Interested In

• ProPetro names former Exelon executive Kyle Crowley to its board
• Vaxart adds retired vice admiral and surgeon to its board
• Merck KGaA to acquire Silence Therapeutics for $1.3 billion